SG Talk

Published September 28, 2021 at 4:13 PM
Mexico’s COVID-19 vaccination campaign is focusing more and more on younger adults, as the country’s third wave appears to be slowing down.

China’s Sinovac vaccine has played a key role in Mexico’s nationwide efforts — and CGTN’s Alasdair Baverstock reports – health authorities continue to rely on it for its effectiveness and ease in storage. 


https://america.cgtn.com/2021/09/28/chin...ccinations

HSA need more data 

(29-09-2021, 12:37 PM)Galilo_l Wrote: [ -> ]HSA need more data 

But don't need more data from Pfizer n Moderna last time.... US vacc

And also no need more data from Novavax...US vacc

O.k. we get the drift...

(29-09-2021, 12:52 PM)RichDad Wrote: [ -> ]But don't need more data from Pfizer n Moderna last time.... US vacc

And also no need more data from Novavax...US vacc

O.k. we get the drift...

No need cuz G is one of the stakeholders 

river spirit said china ones lousy

(29-09-2021, 08:17 PM)WhatDoYouThink? Wrote: [ -> ]river spirit said china ones lousy

Sinovac real world protection is around 20% higher than media report.

Often presented 50.4% is for vaccination in between two weeks.
But after trial, recommendation is three or up to four weeks

https://www.bloomberg.com/news/articles/...using-data
Nearly 1,400 of the 13,000 people who took part in clinical trials of Sinovac’s vaccine, called CoronaVac, received their doses three weeks apart, while most of the volunteers in the Brazil-based trials got the second jab two weeks after the first. The protection rate for the smaller group was nearly 20 percentage points higher than the 50.4% rate observed in the majority, Sinovac said in a written response to Bloomberg News.